Back to Cell Types

RPMI-7951Homo sapiens (Human)Cancer cell line

Also known as: Roswell Park Memorial Institute 7951, RPMI7951, RPMI 7951

🤖 AI SummaryBased on 13 publications

Quick Overview

Human melanoma cell line with BRAF mutations and MAPK pathway activation.

Detailed Summary

RPMI-7951 is a human melanoma cell line derived from a malignant melanoma. It is characterized by the presence of BRAF mutations, which lead to constitutive activation of the MAPK pathway. This cell line is frequently used in research to study the mechanisms of melanoma progression and the effects of targeted therapies. The overexpression of wild-type B-Raf in RPMI-7951 contributes to its growth and survival, making it a valuable model for investigating BRAF-related signaling pathways. Additionally, RPMI-7951 has been utilized in studies examining the role of the MAPK pathway in cancer cell proliferation and the development of resistance to therapeutic agents.

Research Applications

BRAF mutation analysisMAPK pathway activation studiesTargeted therapy developmentResistance mechanism investigation

Key Characteristics

BRAF mutationsMAPK pathway activationWild-type B-Raf overexpression

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1666
Species	Homo sapiens (Human)
Tissue Source	Lymph node[UBERON:UBERON_0000029]

Donor Information

Age	18
Age Category	Adult
Sex	Female
Race	caucasian

Disease Information

Disease	Melanoma
Lineage	Skin
Subtype	Melanoma
OncoTree Code	MEL

DepMap Information

Source Type	ATCC
Source ID	ACH-000348_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Ser166Ter (c.497C>A)	Homozygous	-	from parent cell line SNU-C1
MutationSimple	TERT	c.242_243CC>TT (-138/-139CC>TT)	Unspecified	In promoter	PubMed=23348503
MutationSimple	BRAF	p.Val600Glu (c.1799T>A)	Unspecified	-	PubMed=26214590
Gene deletion	PTEN	-	Hemizygous	-	Wistar

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

12

D13S317

11,12

D16S539

11,12

D18S51

17,18

D19S433

13,15

D21S11

28,31.2

D2S1338

17,23

D3S1358

16,18

D5S818

11

D7S820

11,12

D8S1179

12,13

FGA

27

Penta D

12,13

Penta E

7,18

TH01

9,9.3

TPOX

8

vWA

17,19

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Functional profiling of live melanoma samples using a novel automated platform.

Schuchter L.M., Clark D.P.

PLoS ONE 7:E52760-E52760(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.

Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.

Oncogene 23:8796-8804(2004).

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

Immunocytochemical analysis of cell lines derived from solid tumors.

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

J. Histochem. Cytochem. 49:1369-1378(2001).

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Cancer Res. 48:589-601(1988).

Studies of tumor cell lines derived from patients with malignant melanoma.

Gerner R.E., Kitamura H., Moore G.E.

Oncology 31:31-43(1975).

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

Fogh J., Wright W.C., Loveless J.D.

J. Natl. Cancer Inst. 58:209-214(1977).

Membrane associated antigens of human malignant melanoma V: Serological typing of cell lines using antisera from nonhuman primates.

Bruggen J., Sorg C., Macher E.

Cancer Immunol. Immunother. 5:53-62(1978).

Web Resources

dtp.cancer.gov genome.ucsc.edu